Two-Drug attack before surgery aims to wipe out skin cancer
NCT ID NCT06151236
Summary
This study is testing a combination of two immunotherapy drugs (nivolumab and relatlimab) given to patients before surgery for Merkel cell carcinoma, a rare and aggressive skin cancer. The goal is to see if this 'pre-surgery' treatment can shrink or eliminate the tumor and, most importantly, prevent the cancer from coming back after the operation. The trial will enroll about 20 patients with early to mid-stage cancer that can be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.